Related Experiment Video
Updated: May 29, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Advances in acute lymphoblastic leukemia in adults
1Clinical Hematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona and Universidad Autónoma de Barcelona, Barcelona, Spain. jribera@iconcologia.net
Current Opinion in Oncology
|September 6, 2011
Summary
Recent advances in adult acute lymphoblastic leukemia (ALL) have improved survival rates. New molecular insights, targeted therapies, and optimized treatments are enhancing long-term outcomes for patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute lymphoblastic leukemia (ALL) remains a significant challenge in adult hematologic malignancies.
- Understanding the molecular underpinnings of ALL is crucial for risk stratification and treatment development.
Purpose of the Study:
- To review recent advancements in the diagnosis and treatment of adult acute lymphoblastic leukemia (ALL).
- To highlight progress in understanding the molecular basis and prognostic factors of adult ALL.
Main Methods:
- Literature review of recently published articles on adult ALL.
- Analysis of studies focusing on molecular basis, minimal residual disease, and therapeutic strategies.
Main Results:
- Improved molecular classification leading to precise risk factor definition.
- Minimal residual disease assessment redefining prognostic factors and guiding postremission management.
- Increased survival in young and middle-aged adults due to pediatric-inspired therapies, expanded stem cell transplantation eligibility, targeted therapies, and enhanced supportive care.
Conclusions:
- Current therapeutic modifications are significantly improving long-term outcomes in adult ALL.
- Ongoing studies project long-term survival rates approaching 50% for adult ALL.
- These advancements pave the way for future therapeutic innovations in adult ALL treatment.
